PMID- 32130255
OWN - NLM
STAT- MEDLINE
DCOM- 20200615
LR  - 20231103
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - Omeprazole use and risk of chronic kidney disease evolution.
PG  - e0229344
LID - 10.1371/journal.pone.0229344 [doi]
LID - e0229344
AB  - RATIONALE, AIMS AND OBJECTIVES: In recent years, the use of proton pump 
      inhibitors (PPI), especially omeprazole, has been associated with development of 
      chronic kidney disease (CKD). These drugs are widely used worldwide. Although 
      some studies have found an association between the use of PPI and the onset of 
      acute renal failure and CKD. This study aims to analyze the association between 
      the continuous use of omeprazole and the progression of CKD in adult and elderly 
      individuals. METHOD: A retrospective cohort study was conducted with patients 
      followed up at a nephrology clinic in Brazil, in 2016 and 2017. Information about 
      clinical and sociodemographic data, health behaviors, and medication use were 
      collected from all patients diagnosed with CKD through consultation of medical 
      charts and the Brazilian health information system (SIS). The participants were 
      allocated into two groups: users and non-users of omeprazole, and the progression 
      of CKD was then evaluated for each group. In the bivariate analysis, the 
      Mann-Whitney U test to compare the quantitative variables between groups, and the 
      Pearson/Fisher two-tailed chi-square test to compare the categorical variables 
      were applied. Multivariate analysis was performed using Cox regression. RESULTS: 
      A total of 199 CKD patients were attended in the polyclinic, and of these, 42.7% 
      were omeprazole users. There was a higher percentage of CKD progression in users 
      (70.6%) compared to non-users (10.5%). The hazard ratio was 7.34 (CI: 
      3.94-13.71), indicating a higher risk of progression to worse stages of CKD in 
      omeprazole users than in non-users. As for the other variables, no statistically 
      significant difference was found between groups (p > 0.05). CONCLUSION: An 
      association between omeprazole use and progression of CKD stage was identified, 
      showing a higher risk of disease evolution among omeprazole users.
FAU - Guedes, Joao Victor Marques
AU  - Guedes JVM
AUID- ORCID: 0000-0002-4812-7030
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
FAU - Aquino, Jessica Azevedo
AU  - Aquino JA
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
FAU - Castro, Tassia Lima Bernardino
AU  - Castro TLB
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
FAU - Augusto de Morais, Flavio
AU  - Augusto de Morais F
AD  - Department of Nephrology, Ambulatory of Municipal Polyclinic of Divinopolis, 
      Divinopolis, Minas Gerais, Brazil.
FAU - Baldoni, Andre Oliveira
AU  - Baldoni AO
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
FAU - Belo, Vinicius Silva
AU  - Belo VS
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
FAU - Otoni, Alba
AU  - Otoni A
AD  - Department of Health Sciences, Federal University of Sao Joao Del-Rei (UFSJ), 
      Divinopolis, Minas Gerais, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20200304
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*adverse effects
MH  - Renal Insufficiency, Chronic/*pathology
MH  - Retrospective Studies
MH  - Risk Assessment
PMC - PMC7055824
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/03/05 06:00
MHDA- 2020/06/17 06:00
PMCR- 2020/03/04
CRDT- 2020/03/05 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2020/02/04 00:00 [accepted]
PHST- 2020/03/05 06:00 [entrez]
PHST- 2020/03/05 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2020/03/04 00:00 [pmc-release]
AID - PONE-D-19-23732 [pii]
AID - 10.1371/journal.pone.0229344 [doi]
PST - epublish
SO  - PLoS One. 2020 Mar 4;15(3):e0229344. doi: 10.1371/journal.pone.0229344. 
      eCollection 2020.